Th e interstitial lung diseases (ILDs) encompass a large number of distinct disorders that are characterized by infl ammation and/or fi brosis involving the lung parenchyma. Th ese disorders result from a myriad of potential etiologies including medications, environmental exposures and autoimmune diseases such as myositis. Regardless of etiology, these lung injuries result in a limited number of patterns that are classifi ed based on pathologic appearance into several major subgroups (Table 1) . In general, the pathology impacts prognosis regard less of the etiology of the ILD. Th e target of injury includes the critical alveolar-capillary interface respon sible for gas exchange. As a group, therefore, ILDs result in compromised oxygen absorption as well as decreased lung compliance and increased work of breathing. Th e clinical manifestation of ILD is typically dyspnea on exertion, cough and fatigue.
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Lung involvement in autoimmune myositis was fi rst systematically reviewed in 1974 [1] , although it had been described in individuals and case series since the mid1960s. Since that time, there has been an increasing appreciation of the prevalence and clinical signifi cance of ILD. Recent studies suggest that ILD complications occur in 20 to 65% of individuals with myositis (reviewed in [2] ). Th e wide variation in prevalence refl ects in part the lack of a standard approach to screening for ILD in newly diagnosed patients with myositis. A recent study of 90 histidyl-tRNA synthetase (Jo-1) patients found ILD present in 86% [3] . Alanyl-tRNA synthetase (PL-12) is similarly associated with ILD in 90% or more of patients based on two recent case series [4, 5] . Th e apparently increasing rates of ILD in patients with myositis represent a combi nation of improved diagnostic techniques and increasing awareness of ILD as a presenting symptom of auto immune myositis. Th e mortality associated with ILD has been anecdotally described since the earliest reports. Prospective long-term studies suggest a 40% increase in mortality attributable to ILD [6] . ILD is thus both a common and a highly lethal manifestation of autoimmune myositis.
Cellular and cytokine makeup of the normal and injured lung
Th e normal alveolus has a simple cellular makeup with resident alveolar type I cells arranged along a basement membrane lining the alveolar airspaces. Type II cells occupy the corners of the alveoli and are the source of type I cells in the event of cellular damage. Surrounding the alveoli are fi ne capillary networks lined by endothelial cells. Th e alveolar-capillary interface is a dynamic barrier. Infl ammatory cells including neutrophils, lympho cytes and macrophages travel through the capillary vessels and transit into the alveolar air space. Mature fi broblasts and circulating fi brocytes can also transit through the alveolar basement membrane. Resident antigen-presenting cells, including dendritic cells, serve as key sensors for danger signaling and are principally responsible for infl ammatory cell infl ux.
Because the lung is in constant contact with the exterior, much like the skin, it is in a permanent state of cellular injury and regeneration. Under normal circum stances, type I cells are generated by type II cells and injury does not result in fi brosis. In the setting of more severe injury, or in certain vulnerable hosts, injured type I cells are instead replaced by fi broblasts, possibly from marrowderived circulating fi brocytes. Th e constant cycle of injury and repair in the lung creates a unique opportunity for the development of neoantigens, which is compounded by the frequency of viral encounters in the lung. Indeed, there have been a number of studies that associate the presence of ILD with specifi c viral pathogens [7] [8] [9] .
Patterns of lung injury in myositis
A number of pathologic patterns are associated with myositis ILD. Th e most common patterns documented by surgical lung biopsy in a recent study of Jo-1-associated ILD showed diff use alveolar damage in 55%, usual interstitial pneumonia in 45% and nonspecifi c interstitial pneumonia in 14% [3] . Interestingly, the diagnoses based on chest CT patterns rather than tissue biopsy favored a preponderance of nonspecifi c interstitial pneumonia (50%) while only 30% of CTs were suggestive of usual inter stitial pneumonia. Th is high prevalence of diff use alveolar damage on surgical biopsy probably refl ects a tendency toward performing biopsies in patients who are failing therapy or who present with acute interstitial pneumonia as a fi rst manifestation of myositis. In a recent multicenter series of patients with PL-12, 45% of patients had either biopsy or CT consistent with usual interstitial pneumonia, 16% with nonspecifi c interstitial pneumonia and 16% with cryptogenic organizing pneumonia [4] . Th e pattern of lung injury in myositis ILD thus appears to span the spectrum, but with a higher frequency of usual interstitial pneumonia than is commonly seen in other autoimmune ILDs.
Unique clinical patterns associated with interstitial lung disease
While myositis is traditionally defi ned by the presence of muscle or skin infl ammation, it is increasingly apparent that a subset of patients with myositis-associated antibodies presents either initially or uniquely with ILD. Th is pattern has been highlighted by patients with clinically amyopathic dermatomyositis (CADM), with rapidly progressive and frequently fatal ILD (reviewed in [10] ). Th ese patients might previously have been con sidered to have idiopathic acute interstitial pneumonia. However, increasing awareness of CADM and the dis covery of additional autoantibodies associated with this clinical presentation (see below) will allow more accurate ascertainment of this presentation. Th e occurrence of such a dramatic pulmonary-centric presentation raises the question of whether the primary site of injury might in fact be the lung rather than the muscle.
Prominent autoantibody specifi cities found in patients with myositis and lung disease
Across the spectrum of rheumatic autoimmune diseases, distinct patterns of antibody reactivity are strongly associated with specifi c clinical subgroups -a feature that makes autoantibodies of diagnostic and prognostic use. For example, autoantibodies against topoisomerase I are found in patients with diff use scleroderma and lung disease, whereas antibodies against centromere protein B are found in patients with limited scleroderma and are predictive of digit loss. In patients with idiopathic infl ammatory myopathies, such associations are also found. A well-recognized example of this is the strong association of myositis-specifi c anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies with ILD. Interestingly, emerging data from another recently described dermatomyositis (DM)-specifi c antibody -melanoma diff erentiationinduced gene-5 (MDA-5) -indicates that it is also associated with ILD. Details of these two distinct myositisspecifi c autoantibody types are discussed below.
Aminoacyl-tRNA synthetase autoantibodies
ARSs are ubiquitously expressed, highly conserved cytoplasmic enzymes that perform an essential cellular function: they catalyze the esterifi cation of specifi c amino acids to their cognate tRNA, thus forming an aminoacyltRNA complex. Th ere is a distinct ARS for each of the 20 amino acids. Th e complex transfers the correct amino acid to an elongating polypeptide chain as the ribosome transcribes the coding sequence of mRNA into the appro priate protein. To date, autoantibodies to eight of the ARS enzymes have been identifi ed; these include antibodies against histidyl-tRNA synthetase (Jo-1) [11] , alanyl-tRNA synthetase (PL-12) [12] , threonyl-tRNA synthetase (PL-7) [13] , glycyl-tRNA synthetase (EJ) [14] , isoleucyl-tRNA synthetase (OJ) [14] , asparaginyl-tRNA synthetase (KS) [15] , phenylalanyl-tRNA synthetase (Zo) [16] and tyrosyl-tRNA synthetase (YRS) [17] . Of these, anti-Jo-1 is by far the most frequently found specifi city, occurring in 15 to 20% of myositis patients, whereas the other anti-ARS autoantibodies are found in 1 to 4% of myositis patients [18] . Although anti-ARS antibodies may be found together with other antibodies in some patients (for example, frequently with Ro52), it is noteworthy and intriguing that individuals with anti-ARS antibodies rarely target more than a single synthetase.
Anti-ARS antibodies are associated with a distinct clinical syndrome referred to as the antisynthetase syndrome. Characteristic features (shown in Figure 1 ) include myositis, ILD, nonerosive arthritis, Raynaud's phenomenon, fever and mechanic's hands (hyperkeratotic lesions along the radial and palmar aspects of the fi ngers) [19] . While clinical similarities between patients with diff erent ant-ARSs are striking, noteworthy distinctions between these patient groups have been described.
For example, Kalluri and colleagues recently reported a detailed analysis of the clinical features of 31 subjects with anti-PL-12 antibodies [4] . Th ey found a higher frequency of ILD in these patients compared with those with Jo-1 antibodies (90% versus 50 to 75%), whereas the association with myositis/myalgia was less strong (52% versus 90%). Th ese fi ndings are consistent with those reported by other workers, including a large study of Japanese myositis patients with anti-ARS antibodies performed by Yoshifuji and colleagues [20] . In addition to the clinical experience linking anti-ARS antibodies with lung pathology, a mouse model of anti-Jo-1 immune response demonstrates predominant lung disease [21] . Th is study as well as others correlating anti-Jo1 antibody levels with disease activity [22] raise the possibility that anti-ARS antibodies are pathogenic. However, this remains to be resolved. For years it has been noted that a signifi cant proportion of myositis patients have ILD without autoantibodies [2] , raising the possibility of additional specifi cities that are as yet unidentifi ed. Recent fi ndings show that this may indeed be the case: new myositis-specifi c antibodies continue to be described [23] , including MDA-5 (see below), which was also recently found to associate with ILD. Of interest, these 
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Melanoma diff erentiation-induced gene-5 antibodies
MDA-5 antibodies were fi rst described in 2005 by Sato and colleagues in a study of 103 adult Japanese myositis patients (seen at Keio University in Tokyo) [24] . At the time, these antibodies were named anti-CADM-140 because they recognized a 140 kDa protein in patients and were associated with CADM; the antibodies were found in 8/42 (19%) DM patients and in 0/61 (0%) polymyositis patients, with all eight of the antibody-positive patients having CADM. In this study, the authors reported that the presence of these antibodies was associated with rapidly progres sive ILD, with 50% of the antibody-positive patients having ILD compared with 6% in the antibody-negative group [24] . Th ese authors subse quently identifi ed the 140 kDa autoantigen as a cytoplasmic RNA helicase encoded by MDA-5 [25] . Th is protein is a known RNA virus receptor, thus potentially providing a mechanistic linkage between the development of myositis ILD and viral infection [26] .
Th ese fi ndings have been validated by those of Nakashima and colleagues, who independently and almost simultaneously identifi ed the CADM-140 autoantigen as MDA-5 [27] . Th ey studied an adult Japanese patient cohort seen at Kyoto University Hospital. Eighty-four myositis patients were studied, and anti-MDA-5 antibodies were found in 13/37 (35%) and 0/47 (0%) of DM patients and polymyositis patients, respectively. Of those patients with the antibody, 2/13 had typical DM and 11/13 had CADM. Interestingly, 54% of the anti-MDA-5-positive group had rapidly progressive ILD compared with 4% of the anti-MDA-5-negative sera, consistent with the fi ndings of Sato and colleagues [24] .
Gono and colleagues evaluated the clinical features of patients with MDA-5 antibodies and compared them with those of patients with anti-ARS antibodies in a retro spective study (at Tokyo Women's Medical University) [28] . Th ey identifi ed 65 patients with DM/ CADM, 46 (71%) of whom also had ILD. Amongst this latter group, 24/46 (52%) had either anti-MDA-5 or anti-ARS antibodies. Interesting diff erences were noted when clinical features of the 14 anti-MDA-5-positive patients were compared with the 10 anti-ARS-positive patients. In the former group, the frequency of acute/subacute interstitial pneumonia was signifi cantly higher (71% compared with 20%), the cumulative 60-month survival rate was lower (63% versus 100%), serum ferritin levels were higher (680 ng/ml versus 171 ng/ml) and the median creatinine kinase values were lower (198 IU compared with 1,513 IU). While the numbers in the groups are small, making caution necessary in drawing conclusions, these fi ndings indicate that serum ferritin levels and MDA-5 antibodies may be useful indicators for the early diagnosis of acute/subacute interstitial pneu monia with DM. It is also noteworthy that all three of the above studies showed that MDA-5 antibodies are found exclusively in patients with DM.
New data continue to expand the clinical phenotype associated with MDA-5 autoantibodies. For example, fi nd ings from a recent study of DM patients seen at the Stanford University Department of Dermatology outpatient clinic [29] show that the presence of anti-MDA-5 antibodies is associated with very distinctive cutaneous ulcerations and palmar papules. In this cohort, MDA-5 antibodies also identifi ed a population of DM patients at increased risk for rapid lung disease (22.2% in the anti-MDA-5-positive DM group versus 4.5% in the anti-MDA-5-negative group). Identifying antibodies against MDA-5 in DM patients is therefore of clinical importance, as this specifi city associates with high risk of ILDincluding rapidly progressing ILD, which can lead to patient mortality, as well as cutaneous ulcerations and palmar papules. To date, there are no commercial assays that can be used to identify these antibodies in the clinical setting. Additionally, as mentioned above, it is noteworthy that other as yet unidentifi ed autoantibodies probably do exist in patients with idiopathic infl am matory myopathies and ILD that are at present classifi ed as antibody-negative. Identifi cation of these antibodies may well yield further fi ne specifi city of use for predicting and monitoring distinct clinical subgroups within the spectrum of DM patients with lung disease. Additional studies are also needed to understand why antigens as apparently unrelated as ARS and MDA-5 are such specifi c targets of the autoimmune response in this disease spectrum. Interestingly, several recent reports link anti-polymyositis Scl antibody with a similar phenotype to that of the antisynthetase syndrome [30, 31] . Th e mechanism underlying such similarity is unclear, but might include a shared HLA type or other shared genetic factors.
Mechanisms regulating expression of ARS and MDA-5
While the mechanisms underlying the association of immune responses against specifi c, ubiquitously expressed autoantigens with distinct clinical disease pheno types remain undefi ned, emerging data are focus ing attention on unique expression patterns of the myositis-specifi c autoantigens themselves. Th us, although most auto antigens are ubiquitously expressed, recent in vivo fi ndings show that signifi cant diff erences in expression levels exist in unique microenvironments. Th ese concepts are well illustrated by the examples of ARS and MDA-5, as described below. Such fi ndings of local elevated expression levels of specifi c antigens are of great potential importance in understanding why certain antigens are targeted in specifi c autoimmune diseases, and why the feed-forward loop of autoimmunity is propagated so eff ectively.
Elevated levels of ARS are expressed in normal lung and regenerating muscle cells
Important new insights into the in vivo expression of autoantigens in unique microenvironments within relevant target tissues themselves were made several years ago [32] . While these studies indicate a probable role for damaged muscle in initiating/propagating myositis, they do not address the role of lung; however, the emerging principles may well be applicable to the lung, and are therefore reviewed briefl y below. Th e authors performed immunoblots on lysates made from control and myositis patient muscle biopsies. Unexpectedly, the data showed very low expressed levels of myositis autoantigens such as the ARSs in control muscle. In contrast, these autoantigens were robustly expressed in lysates made from muscle biopsies obtained from myositis patients. Immunohistochemical studies confi rmed that the enhanced autoantigen expression was detected in muscle cells themselves, as well as in infi ltrating infl ammatory cells. Importantly, further characterization of the muscle cell staining confi rmed that the enhanced autoantigen expression was found in the regenerating muscle cells, and not in mature myotubes. Th ese fi ndings demonstrate that mature, healthy muscle is probably not the target of autoimmunity. Instead, injured muscle in which regenerat ing muscle cells (expressing high levels of mysoitis-specifi c autoantigens such as the ARS molecules) are replacing injured cells may be the primary target. Th e direction of the immune response against regenerating muscle cells, critical participants in the healing of muscle injury, probably enables a feed-forward cycle where tissue damage drives antigen expression, immune response and additional tissue damage.
Little is currently known about autoantigen expression in lung. Th e limited data examining levels of myositisspecifi c autoantigens in the lung available to date provide tantalizing evidence that levels of Jo-1 are increased in normal lung relative to the two other normal tissues that were studied (muscle and breast), and that Jo-1 expression in normal lung is robust whereas expression of other myositis autoantigens is minimal (Mi-2 and the catalytic subunit of DNA-dependent protein kinase were the other two autoantigens examined) [32] . Future studies will be important to evaluate whether and which cells in the lung express altered myositis autoantigen levels. Th e regeneration of alveolar type I cells from type II cells mirrors the regeneration of myocytes from muscle satellite cells in some aspects, thus providing a potentially analogous model for antigen upregulation in the lung.
In addition to autoantigen levels, the autoantigen structure plays a critical role in shaping the immune response. Changes in autoantigen structure in response to immune eff ector pathways are particularly relevant to autoimmune tissue injury. Noteworthy in this regard are the structural changes (including generation of novel cleavage fragments) induced when target cells are killed by the cytotoxic lymphocyte granule exocytosis pathway. Granzyme B is a protease that is abundantly expressed in cytotoxic lymphocyte granules. Th is essential host defense mechanism is mediated by cytotoxic lymphocytes and natural killer cells, and has been documented to exist in myositis tissues [33] . Many myositis autoantigens (including Jo-1) are cleaved by granzyme B [34] . Interestingly, a novel form of Jo-1 that is more susceptible to cleavage by granzyme B in the human lung has been demonstrated [35] , raising the possibility that novel Jo-1 cleavage fragments might be generated uniquely in the lung. Th is would result in distinct fragments and consequently cryptic epitope generation during antigen processing.
Of note, the cleavable Jo-1 conformation was not detected in muscle, thus focusing attention on the lung as the possible initiation site for anti-ARS autoimmunity associated with ILD. In this scenario, muscle might become targeted at a later stage, potentially in the setting of later muscle damage, where muscle regeneration induces high levels of Jo-1 -and other myositis-specifi c autoantigen -expression and autoimmune injury. It is of some interest that Jo-1 has been shown to trigger chemokine receptors on T cells and immature dendritic cells [36] , raising a possible mechanistic association between increased antigen expression and infl ammatory cell recruit ment. Whether cleavage of Jo-1 enhances its eff ect on chemokine receptors is not currently known. Further studies examining the expression and cleavability in both the lung and muscle of other ARS molecules and MDA-5 are needed to provide additional context and interpretation.
Substantial evidence has accumulated implicating type I interferons in the pathogenesis of DM [37] . It is noteworthy that both MDA-5 and Ro52 -frequent targets in DM -are type I interferon inducible. Evaluating whether MDA-5 expression is increased in target tissues in DM (lung, muscle and skin) with the ARS/ILD disease spectrum will be informative. Such observations may suggest a potential role for anti-interferon therapies in MDA-5-associated lung disease.
Whether autoantibodies have a direct role in generating and augmenting tissue injury in myositis-associated ILD is very unclear, but there are no available data to support this role. Rather, it is more likely that autoantibody specifi cities refl ect the antigen driving a T-cell response, which more directly results in tissue injury. Data about antigen-specifi c T cells in human ILD in DM/polymyositis are not available, but there are several intriguing studies suggesting that the fulminant onset of ILD associated with myositis is linked to the increased CD8 T cells in the lung that express cytotoxic properties [38, 39] . Th ere are some interesting, although anecdotal, data that suggest treatment of such patients with the T-celldirected agents cyclosporine or FK506 may have a benefi cial eff ect [40, 41] . Defi ning antigen-specifi c CD4 and CD8 T cells in the lung of patients with myositis and ILD may provide very important insights into the mechanism and possibly therapy in these diseases.
Models for targeting the lung in myositis
Two distinct models currently exist, which diff er in the initiation site, that may explain the targeting of the lung in patients with myositis.
One scenario is that the lung is the primary target of the autoimmune response. Here, the presence of suprathreshold levels of Jo-1 or MDA-5 potentially during infection or malignancy may produce novel autoantigen forms. In the setting of an appropriate immune response, autoreactivity to these novel antigens may be produced. In the setting of subsequent muscle injury (for example, muscle overuse or viral infection), the preformed immune response might be directed against regenerating muscle cells that express high levels of myositis autoantigens, thereby focusing the subsequent amplifi cation loop onto muscle.
An alternate model would invoke muscle as the primary target, with the lung being involved as a bystander. In this circumstance, enhanced expression of myositis autoantigens could be caused by muscle damage with increased numbers of regenerating cells, or as a consequence of interferon exposure. Th e subsequent immune response may become focused on the lung, where relevant myositis autoantigens are robustly expressed.
Conclusion
Th e striking targeting of the lung in autoimmune myopathies that are associated with specifi c autoantibody responses (noteworthy examples include MDA-5 and the ARS family of antigens) provides important pathogenic insights. Understanding antigen expression, confor mations and modifi cations in the lung is key to defi ning relevant mechanisms. Whether involvement of the lung in this disease spectrum occurs because it is the primary target or the secondary target of the autoimmune response is currently unknown, but identifying amplifying pathways (for example, interferon or regeneration) may have therapeutic implications.
